Newswise — CHICAGO, IL (April 10, 2015) – Robert L. Coleman, MD, Professor, Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX, started his one-year term as the 47th President of the Society of Gynecologic Oncology (SGO) and fifth President of the Foundation for Gynecologic Oncology at the conclusion of the Society’s 46th Annual Meeting on Women’s Cancer, March 28-31, 2015, in Chicago.

Dr. Coleman, who is also Vice Chair of Clinical Research, Ann Rife Cox Chair in Gynecology and Deputy Chair in the Department of Gynecologic Oncology and Reproductive Medicine at MD Anderson, commented that SGO’s newly formed Health Policy & Socio Economic Committee and the task forces created within it will address important quality and payment issues that are specific to the subspecialty of gynecologic oncology.

“I am excited to be president of the SGO at a time when SGO continues to align its resources to meet the ever changing needs of the members in their practices. I look forward to receiving feedback from these new task forces–Coding and Reimbursement; Future of Physician Payment Reform; Lobbying/Legislative and Regulatory Affairs; Quality, Outcomes and Policy and the Registry—because these issues directly impact the care we provide to our patients and how that is valued by the federal government and insurers,” said Dr. Coleman. “As health care practitioners across the country adapt to the changes brought about by the Affordable Care Act, SGO needs to be the voice of our subspecialty.”

Dr. Coleman’s research interests include novel therapeutics for ovarian, uterine and cervical cancer, clinical trial development and statistical design, surgical innovations and graduate education. In partnership with his department’s faculty, he has established a translational medicine pipeline, which fosters, facilitates and vets promising compounds and treatment strategies from preclinical to clinical investigation. He is MD Anderson’s NRG Oncology Principal Investigator (PI) and is PI or Co-PI for several NRG Oncology prospective clinical trials. He has been instrumental in representing SGO in conversations with the FDA on rethinking trial designs to allow for continued drug development in the ovarian cancer space.

Dr. Coleman has authored and co-authored more than 500 scientific publications. These include more than 215 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks such as The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers, Prognostic and Predictive Factors in Gynecological Cancers, and most recently, An Atlas of Gynecologic Oncology. He serves on the Editorial Board of several peer-reviewed scientific publications.

In addition to his leadership position within the SGO, Dr. Coleman is an active member of many national organizations, including the American College of Surgeons, American Association for Cancer Research and the American Society of Clinical Oncology. He also serves several international organizations, such as the International Gynecologic Cancer Society, European Society of Gynecologic Oncology and the European Society of Medical Oncology.

# # #

About SGOThe Society of Gynecologic Oncology (SGO) is a 501(c) 6 national medical specialty organization of physicians and allied health care professionals who are trained in the comprehensive management of women with malignancies of the reproductive tract. The Society’s membership, totaling more than 2,000, is primarily comprised of gynecologic oncologists, as well as other related medical specialists including medical oncologists, radiation oncologists, nurses, and pathologists. SGO members provide multidisciplinary cancer treatment including chemotherapy, radiation therapy, surgery and supportive care.

About the FoundationThe Foundation for Gynecologic Oncology is a 501(c)3 organization that ensures that SGO meets the needs and provides the resources for members and the women’s cancer care community.